CER Daily Newsfeed

Proton vs Photon RT in Breast Cancer: Which Is Better?

(11/10, M. Alexander Otto, PA, MMSc, Medscape) reports “Following similar results in prostate and throat cancer, a recent phase 3 trial found that proton radiotherapy (RT) failed to improve patient-reported outcomes over photon RT in women with breast cancer undergoing adjuvant radiation.” Full

Gefurulimab for MG Exhibits Lasting Efficacy, Safety in Topline PREVAIL Trial Data

(11/8, Maggie L. Shaw, The American Journal of Managed Care) reports “Gefurulimab showed significant improvements in MG-ADL and QMG scores in the phase 3 PREVAIL trial, with early benefits sustained through week 26. Administered subcutaneously, gefurulimab offers convenience over conventional monoclonal antibodies, with a prefilled syringe or autoinjector.” Full

Video: Steroidal vs Nonsteroidal MRAs in Heart Failure

(11/10, Nihar Desai, MD, MPH, Josephine Harrington, MD , Ken Cohen, MD, FACP, The American Journal of Managed Care) “Panelists discuss how nonsteroidal MRAs like finerenone differ mechanistically from steroidal MRAs by lacking steroid rings (reducing steroid-related adverse effects like gynecomastia), having different mineralocorticoid receptor binding patterns, shorter half-lives, and potentially lower hyperkalemia risk, with strong evidence supporting their use in heart failure with preserved ejection fraction and additive benefits when combined with SGLT2 inhibitors.” View Video

NICE Breaks New Ground In England As Abiraterone Becomes First Generic Drug To Win Funding

(11/7, Neena Brizmohun, Pink Sheet) reports “...As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.” Subscription Required

England’s NICE Defends Its Processes, But Recognizes ‘Tough’ Climate For Industry

(11/7, Eliza Slawther, Pink Sheet) reports “...Sam Roberts, chief executive of England’s NICE, has defended the health technology assessment institute’s cost-effectiveness thresholds and the country’s ranking against other nations when it comes to market access, while acknowledging that the UK’s pharma ecosystem is ‘really tough.’” Subscription Required

Market Access and HTA – A Snapshot of Recent Developments with Sreeram Ramagopalan: July–September 2025

(11/10, Sreeram Ramagopalan, The Evidence Base) comments “...First, pharmaceutical manufacturers must fundamentally shift their strategic approach – success now requires proactive evidence generation aligned with diverse payer requirements and thoughtful clinical trial design with head-to-head comparisons where feasible. Second, the field is slowly but positively moving toward recognizing that equity considerations are not peripheral but central to access decisions, as seen in Australia's prominent focus on First Nations health and pediatric access. Ultimately, demonstrating genuine therapeutic value through robust evidence is becoming the universal currency for market access across all healthcare systems.” Full